

Please type a plus sign (+) inside this box ➔ +

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

| | | | |
|---|--------|--------------------------|----------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Complete if Known | |
| | | Application Number | 10/580,170 |
| | | Filing Date | May 24, 2007 |
| | | First Named Inventor | Guillermo MOR |
| | | Group Art Unit | 1643 |
| | | Examiner Name | To be Assigned |
| | | Attorney Docket Number | YALE-106/00US |
| Sheet | 1 of 1 | | |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|--|--------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ² |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| OTHER – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| /C.Y./ | C1 | KAMSTEEG, <i>et al.</i> , "Phenoxodiol – an isoflavone analog – induces apoptosis in chemoresistant ovarian cancer cells," <i>Oncogene</i> , 22(17), pp. 2611-2620, (May 1, 2003) XP002455201. | |
| /C.Y./ | C2 | FLICK, <i>et al.</i> , "Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients," <i>Journal of Society of Gynecologic Investigation.</i> , 11(4), pp. 252-259, (May 4, 2004) XP009088472. | |
| /C.Y./ | C3 | Supplementary European Search Report based on International Application No. PCT/US2004/039650, (October 30, 2007). | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|---------------------------------|-----------------|------------|
| Examiner Signature | /Christopher Yaen/ (03/11/2009) | Date Considered | 03/11/2009 |
|--------------------|---------------------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number (optional). ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.